Key Information
For more information please contact your NET centre and the Principal Investigator, alternately contact NECA NET Nurse Dana Hart dana@neuroendocrine.org.au
Commenced: 2022
Completion due: 2027
Introduction
“Our trial is a world first and the knowledge generated will inform health care policy to completely transform the way people with neuroendocrine cancer, and other rare cancers in the future, are cared for.” – David Chan
Neuroendocrine tumours (NETs) are rare cancers that affect fewer than 1 in 5,000 Australians, but those who live with them suffer from a lot of distressing symptoms and treatment side effects. Rare conditions such as NETs do not receive medical advancements at the same rate as common ones. Under our current health system, the needs of cancer survivors are not always met. Our health system, particularly acute care, is under extreme strain which impacts the care available to patients.
Goal
To improve patient quality of life and develop a cost-effective system that can be implemented across other rare cancers in the future.
Rethinking the health care system to represent a share-care model, including support from General Practitioners and local health workers to address unmet needs of people with Neuroendocrine Tumours and relieve pressure from specialist care.
Aims
Implement a new share-care model for the care of people with neuroendocrine tumours focusing on including local health professionals, including GPs, in the follow-up structure, moving patients away from hospitals and acute care.
Improve the model of care for patients with neuroendocrine tumours, and other rare cancers in the future.
Chief Investigator
Professor Raymond Chan
Collaborators
- University of Melbourne, Melbourne, Victoria
- Peter MacCallum Cancer Centre, Melbourne, Victoria
- Queensland University of Technology, Brisbane, Queensland
- The Queen Elizabeth Hospital, Adelaide, South Australia
- Royal Brisbane and Women’s Hospital, Brisbane, Queensland
- Royal North Shore Hospital, Sydney, New South Wales
- Fiona Stanley Hospital, Perth, Western Australia
Project Partners
- Neuroendocrine Cancer Australia (NECA)
- Primary Care Collaborative Cancer Clinical Trials Group (PC4)
- Royal Australasian College for General Practitioners (RACGP)
- Australian Healthcare and Hospitals Association (AHHA)
- Cancer Nurses Society of Australia (CNSA)
Study Sites
- Peter MacCallum Cancer Centre, Melbourne, Victoria (Principal Investigator – Prof Michael Michael)
- The Queen Elizabeth Hospital, Adelaide, South Australia (Principal Investigator – A/Prof Gaby Cehic)
- Royal Brisbane and Women’s Hospital, Brisbane, Queensland (Principal Investigator – A/ Prof David Wyld)
- Royal North Shore Hospital, Sydney, New South Wales (Principal Investigator – Dr David Chan
- Fiona Stanley Hospital, Perth, Western Australia (Principal Investigator – Dr David Ransom)
